Read the January/February 2020 edition of Pharmafocus online now!

pharmafile | January 30, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, US, brexit, coronavirus, opioid crisis, pharma 

Pharmafocus returns for the New Year with its January/February issue, and things have certainly changed since we left. Brexit got done – or at least, the first step in a long process – and the UK will leave the European Union at 11pm on 31 January.

It’s a path paved with uncertainty, but it does provide clarity for business and industry which have been previously unable to plan ahead in such a divided climate. But the challenges ahead will be great, and are embodied in the news that NHS waiting times have now hit the worst level ever recorded.

But if you can’t get enough of the continuing drama of Brexit, you don’t need to wait long until the next seismic political event; the US Presidential Election is looming in November, and the Democratic Party will name its nominee for the presidency in July, a decision that will set the stage for a showdown with sitting President Donald Trump on key issues like drug pricing and the opioid crisis.

These issues will be of the utmost importance to voters in a climate where the tightening grip of conspiracy theories and anti-vaccine disinformation has caused measles rates to rocket to its highest rate in 27 years. In a special feature, Pharmafocus looks at each of the presidential candidates and their plans to tackle the opioid epidemic.

Elsewhere in the issue, we document the first chapters of the ongoing Wuhan coronavirus outbreak, cover the latest wave of drug price hikes from Big Pharma in the US, and examine why the WHO is warning that efforts against antimicrobial resistance are under threat.

This month, we also welcome Conor Kavanagh, who has joined the Pharmafocus team as Editorial Assistant/Journalist.

Read the January/February issue online for free here!

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and …

Latest content